Luca Rastelli

Luca Rastelli

Company: Kleo Pharmaceuticals

Job title: CSO


A Novel First in Class ex vivo Combination Between NK cells & a CD38 Targeting Antibody Recruiting Molecule as a Novel Approach to Arm NK Cells Without Cellular Engineering for the Treatment of Multiple Myeloma 4:40 pm

• Kleo has developed Antibody Recruiting Molecule as a novel chemical platform to target NK cells without cellular engineering relies • ARM are synthetic, bifunctional molecules that bind to a target, e.g. tumor antigen like CD38 or viral antigen like Sars-Cov2 Spike protein, and simultaneously recruit endogenous IgG harnessing FcR dependent effector cells including NK…Read more

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.